Alvogen Advances Its Branded Offering Via Agreements
By licensing Covis’ Alvesco ciclesonide inhaler in central and eastern Europe, as well as preparing to launch thee Qysmia weight-loss brand for which it just obtained approval in Korea, Alvogen is expanding its portfolio of branded drugs.
You may also be interested in...
Deal Watch: Themis Leverages Measles Vector Platform In Collaboration With Merck & Co.
In its first big pharma deal, Austrian biotech will develop experimental vaccines for Merck against an undisclosed target. Innovent licenses Chinese rights to Lilly diabetes candidate, while Novartis gets option to Iconic’s preclinical ophthalmology program.
Alvogen Expands In CEE With Exeltis Portfolio
Alvogen has struck a deal with Insud’s Exeltis to gain rights to 23 women’s healthcare brands in Russia, Ukraine and Kazakhstan.
Pressure Mounts For German Tender Reforms
Germany’s off-patent industry association, Pro Generika, is finding ample support for its position that by awarding tender contracts to exclusive suppliers, health insurance funds are contributing to drug shortages in the country.